Drug resistance in vectorborne parasites: Multiple actors and scenarios for an evolutionary arms race

FEMS Microbiology Reviews

Volumn 38, Issue 1, 2014, Pages 41-55

  Vanaerschot, Manu ^a   Huijben, Silvie ^b   Van den Broeck, Frederik ^a,c   Dujardin, Jean Claude ^a,d  

^a INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^b PENNSYLVANIA STATE UNIVERSITY   (United States)

^c UNIVERSITY OF LEUVEN   (Belgium)

^d UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

Fitnesscost; Leishmania; Plasmodium; Schistosoma; Vectorbornediseases; Virulence

Indexed keywords

ARTEMISININ; CHLOROQUINE; OXAMNIQUINE; PRAZIQUANTEL; PYRIMETHAMINE PLUS SULFADOXINE;

CHEMOTHERAPY; ENVIRONMENTAL FACTOR; HUMAN; LEISHMANIA; LEISHMANIASIS; MALARIA; NONHUMAN; PARASITE; PLASMODIUM; REVIEW; SCHISTOSOMA; SCHISTOSOMIASIS;

SCHISTOSOMA;

FITNESS COST; LEISHMANIA; PLASMODIUM; SCHISTOSOMA; VECTORBORNE DISEASES; VIRULENCE;

ANIMALS; ANTIPARASITIC AGENTS; BIOLOGICAL EVOLUTION; DISEASE VECTORS; DRUG RESISTANCE; HOST-PARASITE INTERACTIONS; HUMANS; PARASITES;

EID: 84891624138     PISSN: 01686445     EISSN: 15746976     Source Type: Journal    
DOI: 10.1111/1574-6976.12032     Document Type: Review

References (132)

1. Abdel-Muhsin AM, Mackinnon MJ, Ali E, Nassir E, Suleiman S, Ahmed S, Walliker D & Babiker HA (2004) Evolution of drug-resistance genes in Plasmodium falciparum in an area of seasonal malaria transmission in Eastern Sudan. J Infect Dis 189: 1239-1244.
2. Agola LE, Mburu DN, DeJong RJ, Mungai BN, Muluvi GM, Njagi EN, Loker ES & Mkoji GM (2006) Microsatellite typing reveals strong genetic structure of Schistosoma mansoni from localities in Kenya. Infect Genet Evol 6: 484-490.
3. Agola LE, Steinauer ML, Mburu DN, Mungai BN, Mwangi IN, Magoma GN, Loker ES & Mkoji GM (2009) Genetic diversity and population structure of Schistosoma mansoni within human infrapopulations in Mwea, central Kenya assessed by microsatellite markers. Acta Trop 111: 219-225.
4. Ammar EM, Said SA & Eissa LA (2002) Mediation of the schistosomicidal effect of praziquantel through nitric oxide. Arzneimittelforschung 52: 844-848.
5. Anderson RM & May RM (1991) Infectious Diseases of Humans: Dynamics and Control. Oxford University Press, Oxford.
6. Andersson DI & Hughes D (2011) Persistence of antibiotic resistance in bacterial populations. FEMS Microbiol Rev 35: 901-911.
7. Aslan H, Dey R, Meneses C et al. (2013) A new model of progressive visceral leishmaniasis in hamsters by natural transmission via bites of vector sand flies. J Infect Dis 207: 1328-1338.
8. Auburn S, Campino S, Miotto O et al. (2012) Characterization of within-host Plasmodium falciparum diversity using next-generation sequence data. PLoS ONE 7: e32891.
9. Babiker HA, Satti G, Ferguson H, Bayoumi R & Walliker D (2005) Drug resistant Plasmodium falciparum in an area of seasonal transmission. Acta Trop 94: 260-268.
10. Babiker HA, Hastings IM & Swedberg G (2009) Impaired fitness of drug-resistant malaria parasites: evidence and implication on drug-deployment policies. Expert Rev Anti Infect Ther 7: 581-593.
11. Beck S, Mockenhaupt FP, Bienzle U, Eggelte TA, Thompson WN & Stark K (2001) Multiplicity of Plasmodium falciparum infection in pregnancy. Am J Trop Med Hyg 65: 631-636.
12. Becker B, Mehlhorn H, Andrews P, Thomas H & Eckert J (1980) Light and electron microscopic studies on the effect of praziquantel on Schistosoma mansoni, Dicrocoelium dendriticum, and Fasciola hepatica (Trematoda) in vitro. Z Parasitenkd 63: 113-128.
13. Bhattarai NR, Das ML, Rijal S et al. (2009) Natural infection of Phlebotomus argentipes with Leishmania and other trypanosomatids in a visceral leishmaniasis endemic region of Nepal. Trans R Soc Trop Med Hyg 103: 1087-1092.
14. Botros S, Sayed H, Amer N, El-Ghannam M, Bennett JL & Day TA (2005) Current status of sensitivity to praziquantel in a focus of potential drug resistance in Egypt. Int J Parasitol 35: 787-791.
15. Cioli D, Picamattoccia L & Moroni R (1992) Schistosoma mansoni: hycanthone/oxamniquine resistance is controlled by a single autosomal recessive gene. Exp Parasitol 75: 425-432.
16. Cioli D, Pica-Mattoccia L & Archer S (1993) Drug resistance in schistosomes. Parasitol Today 9: 162-166.
17. Cioli D, Picamattoccia L & Archer S (1995) Antischistosomal drugs - past, present... and future. Pharmacol Ther 68: 35-85.
18. Cioli D, Botros SS, Wheatcroft-Francklow K et al. (2004) Determination of ED50 values for praziquantel in praziquantel-resistant and -susceptible Schistosoma mansoni isolates. Int J Parasitol 34: 979-987.
19. Cojean S, Houze S, Haouchine D et al. (2012) Leishmania resistance to miltefosine associated with genetic marker. Emerg Infect Dis 18: 704-706.
20. Coles GC (2002) Sustainable use of anthelmintics in grazing animals. Vet Rec 151: 165-169.
21. de Roode JC, Culleton R, Bell AS & Read AF (2004) Competitive release of drug resistance following drug treatment of mixed Plasmodium chabaudi infections. Malar J 3: 33.
22. Decuypere S, Vanaerschot M, Brunker K, Imamura H, Muller S, Khanal B, Rijal S, Dujardin JC & Coombs GH (2012) Molecular mechanisms of drug resistance in natural Leishmania populations vary with genetic background. PLoS Negl Trop Dis 6: e1514.
23. Ding XC, Beck HP & Raso G (2011) Plasmodium sensitivity to artemisinins: magic bullets hit elusive targets. Trends Parasitol 27: 73-81.
24. Doenhoff MJ & Pica-Mattoccia L (2006) Praziquantel for the treatment of schistosomiasis: its use for control in areas with endemic disease and prospects for drug resistance. Expert Rev Anti Infect Ther 4: 199-210.
25. Doenhoff MJ, Kusel JR, Coles GC & Cioli D (2002) Resistance of Schistosoma mansoni to praziquantel: is there a problem? Trans R Soc Trop Med Hyg 96: 465-469.
26. Doenhoff MJ, Hagan P, Cioli D, Southgate V, Pica-Mattoccia L, Botros S, Coles G, Tchuente LAT, Mbaye A & Engels D (2009) Praziquantel: its use in control of schistosomiasis in sub-Saharan Africa and current research needs. Parasitology 136: 1825-1835.
27. Dondorp AM, Nosten F, Yi P et al. (2009) Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med 361: 455-467.
28. Dondorp AM, Yeung S, White L, Nguon C, Day NP, Socheat D & von Seidlein L (2010) Artemisinin resistance: current status and scenarios for containment. Nat Rev Microbiol 8: 272-280.
29. Dorlo TP, Balasegaram M, Beijnen JH & de Vries PJ (2012) Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis. J Antimicrob Chemother 67: 2576-2597.
30. Downing T, Imamura H, Decuypere S et al. (2011) Whole genome sequencing of multiple Leishmania donovani clinical isolates provides insights into population structure and mechanisms of drug resistance. Genome Res 21: 2143-2156.
31. Downing T, Stark O, Vanaerschot M et al. (2012) Genome-wide SNP and microsatellite variation illuminate population-level epidemiology in the Leishmania donovani species complex. Infect Genet Evol 12: 149-159.
32. Ecker A, Lakshmanan V, Sinnis P, Coppens I & Fidock DA (2011) Evidence that mutant PfCRT facilitates the transmission to mosquitoes of chloroquine-treated Plasmodium gametocytes. J Infect Dis 203: 228-236.
33. El-Bassiouni EA, Helmy MH, Saad EI, El-Nabi Kamel MA, Abdel-Meguid E & Hussein HS (2007) Modulation of the antioxidant defence in different developmental stages of Schistosoma mansoni by praziquantel and artemether. Br J Biomed Sci 64: 168-174.
34. el-Lakkany NM, el-Din SH, Sabra AN & Hammam OA (2011) Pharmacodynamics of mefloquine and praziquantel combination therapy in mice harbouring juvenile and adult Schistosoma mansoni. Mem Inst Oswaldo Cruz 106: 814-822.
35. Feng ZL, Curtis J & Minchella DJ (2001) The influence of drug treatment on the maintenance of schistosome genetic diversity. J Math Biol 43: 52-68.
36. Frezard F & Demicheli C (2010) New delivery strategies for the old pentavalent antimonial drugs. Expert Opin Drug Deliv 7: 1343-1358.
37. Garcia-Hernandez R, Manzano JI, Castanys S & Gamarro F (2012) Leishmania donovani develops resistance to drug combinations. Plos Negl Trop Dis 6: e1974.
38. Geerts S & Gryseels B (2000) Drug resistance in human helminths: current situation and lessons from livestock. Clin Microbiol Rev 13: 207-222.
39. Gower CM, Gouvras AN, Lamberton PH et al. (2012) Population genetic structure of Schistosoma mansoni and Schistosoma haematobium from across six sub-Saharan African countries: implications for epidemiology, evolution and control. Acta Trop. DOI: 10.1016/j.actatropica.2012.09.014 [Epub ahead of print].
40. 2+ channels and praziquantel in flatworm neuromusculature. Parasitology 131: S97-S108.
41. Gryseels B, Polman K, Clerinx J & Kestens L (2006) Human schistosomiasis. Lancet 368: 1106-1118.
42. Haldar AK, Sen P & Roy S (2011) Use of antimony in the treatment of leishmaniasis: current status and future directions. Mol Biol Int 2011: 571242.
43. Harrington WE, Mutabingwa TK, Muehlenbachs A, Sorensen B, Bolla MC, Fried M & Duffy PE (2009) Competitive facilitation of drug-resistant Plasmodium falciparum malaria parasites in pregnant women who receive preventive treatment. P Natl Acad Sci USA 106: 9027-9032.
44. Hastings IM (2004) The origins of antimalarial drug resistance. Trends Parasitol 20: 512-518.
45. Hayward R, Saliba KJ & Kirk K (2005) pfmdr1 mutations associated with chloroquine resistance incur a fitness cost in Plasmodium falciparum. Mol Microbiol 55: 1285-1295.
46. Huijben S, Nelson WA, Wargo AR, Sim DG, Drew DR & Read AF (2010) Chemotherapy, within-host ecology and the fitness of drug-resistant malaria parasites. Evolution 64: 2952-2968.
47. Huijben S, Sim DG, Nelson WA & Read AF (2011) The fitness of drug-resistant malaria parasites in a rodent model: multiplicity of infection. J Evol Biol 24: 2410-2422.
48. Hyde JE (2005) Drug-resistant malaria. Trends Parasitol 21: 494-498.
49. Ismail M, Botros S, Metwally A, William S, Farghally A, Tao LF, Day TA & Bennett JL (1999) Resistance to praziquantel: direct evidence from Schistosoma mansoni isolated from Egyptian villagers. Am J Trop Med Hyg 60: 932-935.
50. James CE, Hudson AL & Davey MW (2009) Drug resistance mechanisms in helminths: is it survival of the fittest? Trends Parasitol 25: 328-335.
51. Juliano JJ, Porter K, Mwapasa V, Sem R, Rogers WO, Ariey F, Wongsrichanalai C, Read A & Meshnick SR (2010) Exposing malaria in-host diversity and estimating population diversity by capture-recapture using massively parallel pyrosequencing. P Natl Acad Sci USA 107: 20138-20143.
52. Kasinathan RS, Goronga T, Messerli SM, Webb TR & Greenberg RM (2010a) Modulation of a Schistosoma mansoni multidrug transporter by the antischistosomal drug praziquantel. FASEB J 24: 128-135.
53. Kasinathan RS, Morgan WM & Greenberg RM (2010b) Schistosoma mansoni express higher levels of multidrug resistance-associated protein 1 (SmMRP1) in juvenile worms and in response to praziquantel. Mol Biochem Parasitol 173: 25-31.
54. Kaye B & Woolhouse NM (1976) The metabolism of oxamniquine - a new schistosomicide. Ann Trop Med Parasitol 70: 323-328.
55. Keiser J & Utzinger J (2007) Artemisinins and synthetic trioxolanes in the treatment of helminth infections. Curr Opin Infect Dis 20: 605-612.
56. Keiser J, Manneck T & Vargas M (2011) Interactions of mefloquine with praziquantel in the Schistosoma mansoni mouse model and in vitro. J Antimicrob Chemother 66: 1791-1797.
57. Klein EY, Smith DL, Boni MF & Laxminarayan R (2008) Clinically immune hosts as a refuge for drug-sensitive malaria parasites. Malar J 7: 67.
58. Kokwaro GO & Taylor G (1991) Oxamniquine pharmacokinetics in healthy Kenyan African volunteers. East Afr Med J 68: 359-364.
59. Konate L, Zwetyenga J, Rogier C, Bischoff E, Fontenille D, Tall A, Spiegel A, Trape JF & Mercereau-Puijalon O (1999) Variation of Plasmodium falciparum msp1 block 2 and msp2 allele prevalence and of infection complexity in two neighbouring Senegalese villages with different transmission conditions. Trans R Soc Trop Med Hyg 93(suppl 1): 21-28.
60. Krauth-Siegel RL & Comini MA (2008) Redox control in trypanosomatids, parasitic protozoa with trypanothione-based thiol metabolism. Biochim Biophys Acta 1780: 1236-1248.
61. Laufer MK, Thesing PC, Eddington ND, Masonga R, Dzinjalamala FK, Takala SL, Taylor TE & Plowe CV (2006) Return of chloroquine antimalarial efficacy in Malawi. N Engl J Med 355: 1959-1966.
62. Laufer MK, Takala-Harrison S, Dzinjalamala FK, Stine OC, Taylor TE & Plowe CV (2010) Return of chloroquine-susceptible falciparum malaria in Malawi was a reexpansion of diverse susceptible parasites. J Infect Dis 202: 801-808.
63. Lensen A, Bril A, van de Vegte M, van Gemert GJ, Eling W & Sauerwein R (1999) Plasmodium falciparum: infectivity of cultured, synchronized gametocytes to mosquitoes. Exp Parasitol 91: 101-103.
64. Leprohon P, Legare D, Raymond F, Madore E, Hardiman G, Corbeil J & Ouellette M (2009) Gene expression modulation is associated with gene amplification, supernumerary chromosomes and chromosome loss in antimony-resistant Leishmania infantum. Nucleic Acids Res 37: 1387-1399.
65. Liang YS, Coles GC, Dai JR, Zhu YC & Doenhoff MJ (2001) Biological characteristics of praziquantel-resistant and -susceptible isolates of Schistosoma mansoni. Ann Trop Med Parasitol 95: 715-723.
66. Magesa SM, Mdira KY, Babiker HA, Alifrangis M, Farnert A, Simonsen PE, Bygbjerg IC, Walliker D & Jakobsen PH (2002) Diversity of Plasmodium falciparum clones infecting children living in a holoendemic area in north-eastern Tanzania. Acta Trop 84: 83-92.
67. Mannaert A, Downing T, Imamura H & Dujardin JC (2012) Adaptive mechanisms in pathogens: universal aneuploidy in Leishmania. Trends Parasitol 28: 370-376.
68. Menendez C, Serra-Casas E, Scahill MD et al. (2011) HIV and placental infection modulate the appearance of drug-resistant Plasmodium falciparum in pregnant women who receive intermittent preventive treatment. Clin Infect Dis 52: 41-48.
69. Messerli SM, Kasinathan RS, Morgan W, Spranger S & Greenberg RM (2009) Schistosoma mansoni P-glycoprotein levels increase in response to praziquantel exposure and correlate with reduced praziquantel susceptibility. Mol Biochem Parasitol 167: 54-59.
70. Mita T, Venkatesan M, Ohashi J et al. (2011) Limited geographical origin and global spread of sulfadoxine-resistant dhps alleles in Plasmodium falciparum populations. J Infect Dis 204: 1980-1988.
71. Modabber F (2010) Leishmaniasis vaccines: past, present and future. Int J Antimicrob Agents 36(suppl 1): S58-S61.
72. Mookerjee BJ, Mookerjee A, Sen P et al. (2006) Sodium antimony gluconate induces generation of reactive oxygen species and nitric oxide via phosphoinositide 3-kinase and mitogen-activated protein kinase activation in Leishmania donovani-infected macrophages. Antimicrob Agents Chemother 50: 1788-1797.
73. Mukherjee B, Mukhopadhyay R, Bannerjee B et al. (2013) Antimony-resistant but not antimony-sensitive Leishmania donovani up-regulates host IL-10 to overexpress multidrug-resistant protein 1. P Natl Acad Sci USA 110: E575-E582.
74. Mukhopadhyay R, Mukherjee S, Mukherjee B et al. (2011) Characterisation of antimony-resistant Leishmania donovani isolates: biochemical and biophysical studies and interaction with host cells. Int J Parasitol 41: 1311-1321.
75. Muller IB & Hyde JE (2010) Antimalarial drugs: modes of action and mechanisms of parasite resistance. Future Microbiol 5: 1857-1873.
76. Nair S, Williams JT, Brockman A et al. (2003) A selective sweep driven by pyrimethamine treatment in southeast asian malaria parasites. Mol Biol Evol 20: 1526-1536.
77. Nkhoma SC, Nair S, Cheeseman IH, Rohr-Allegrini C, Singlam S, Nosten F & Anderson TJ (2012) Close kinship within multiple-genotype malaria parasite infections. Proc Biol Sci 279: 2589-2598.
78. Obonyo CO, Muok EM & Mwinzi PN (2010) Efficacy of artesunate with sulfalene plus pyrimethamine versus praziquantel for treatment of Schistosoma mansoni in Kenyan children: an open-label randomised controlled trial. Lancet Infect Dis 10: 603-611.
79. Odogwu SE, Ramamurthy NK, Kabatereine NB, Kazibwe F, Tukahebwa E, Webster JP, Fenwick A & Stothard JR (2006) Schistosoma mansoni in infants (aged < 3 years) along the Ugandan shoreline of Lake Victoria. Ann Trop Med Parasitol 100: 315-326.
80. Ord R, Alexander N, Dunyo S, Hallett R, Jawara M, Targett G, Drakeley CJ & Sutherland CJ (2007) Seasonal carriage of pfcrt and pfmdr1 alleles in Gambian Plasmodium falciparum imply reduced fitness of chloroquine-resistant parasites. J Infect Dis 196: 1613-1619.
81. Ostyn B, Gidwani K, Khanal B, Picado A, Chappuis F, Singh SP, Rijal S, Sundar S & Boelaert M (2011) Incidence of symptomatic and asymptomatic Leishmania donovani infections in high-endemic foci in India and Nepal: a prospective study. PLoS Negl Trop Dis 5: e1284.
82. Paget-McNicol S & Saul A (2001) Mutation rates in the dihydrofolate reductase gene of Plasmodium falciparum. Parasitology 122: 497-505.
83. Pax R, Bennett JL & Fetterer R (1978) A benzodiazepine derivative and praziquantel: effects on musculature of Schistosoma mansoni and Schistosoma japonicum. Naunyn Schmiedebergs Arch Pharmacol 304: 309-315.
84. Pereira C, Fallon PG, Cornette J, Capron A, Doenhoff MJ & Pierce RJ (1998) Alterations in cytochrome-c oxidase expression between praziquantel-resistant and susceptible strains of Schistosoma mansoni. Parasitology 117(Pt 1): 63-73.
85. Perry MR, Wyllie S, Prajapati VK, Feldmann J, Sundar S, Boelaert M & Fairlamb AH (2011) Visceral leishmaniasis and arsenic: an ancient poison contributing to antimonial treatment failure in the Indian subcontinent? PLoS Negl Trop Dis 5: e1227.
86. Peters JM, Chen N, Gatton M, Korsinczky M, Fowler EV, Manzetti S, Saul A & Cheng Q (2002) Mutations in cytochrome b resulting in atovaquone resistance are associated with loss of fitness in Plasmodium falciparum. Antimicrob Agents Chemother 46: 2435-2441.
87. Pica-Mattoccia L, Archer S & Cioli D (1992) Hycanthone resistance in schistosomes correlates with the lack of an enzymatic-activity which produces the covalent binding of hycanthone to parasite macromolecules. Mol Biochem Parasitol 55: 167-175.
88. Pica-Mattoccia L, Dias LC, Moroni R & Cioli D (1993) Schistosoma mansoni: genetic complementation analysis shows that two independent hycanthone/oxamniquine-resistant strains are mutated in the same gene. Exp Parasitol 77: 445-449.
89. Pica-Mattoccia L, Carlini D, Guidi A, Cimica V, Vigorosi F & Cioli D (2006) The schistosome enzyme that activates oxamniquine has the characteristics of a sulfotransferase. Mem Inst Oswaldo Cruz 101: 307-312.
90. Price RN, Dorsey G, Ashley EA et al. (2007) World Antimalarial Resistance Network I: clinical efficacy of antimalarial drugs. Malar J 6: 119.
91. Prichard R (2001) Genetic variability following selection of Haemonchus contortus with anthelmintics. Trends Parasitol 17: 445-453.
92. Read AF & Huijben S (2009) Evolutionary biology and the avoidance of antimicrobial resistance. Evol Appl 2: 40-51.
93. Read AF & Taylor LH (2001) The ecology of genetically diverse infections. Science 292: 1099-1102.
94. Read AF, Day T & Huijben S (2011) The evolution of drug resistance and the curious orthodoxy of aggressive chemotherapy. P Natl Acad Sci USA 108(suppl 2): 10871-10877.
95. Rijal S, Ostyn B, Uranw S et al. (2013) Increasing failure of miltefosine in the treatment of kala-azar in Nepal and the potential role of parasite drug resistance, re-infection or non-compliance. Clin Infect Dis 56: 1530-1538.
96. Rougeron V, De MT, Kako OS, Hide M & Banuls AL (2010) "Everything you always wanted to know about sex (but were afraid to ask)" in Leishmania after two decades of laboratory and field analyses. PLoS Pathog 6: e1001004.
97. Rudge JW, Carabin H, Balolong E, Tallo V, Shrivastava J, Lu DB, Basanez MG, Olveda R, McGarvey ST & Webster JP (2008) Population genetics of Schistosoma japonicum within the Philippines suggest high levels of transmission between humans and dogs. PLoS Negl Trop Dis 2: e340.
98. Secor WE & Colley DG (2005) Schistosomiasis. Springer, Boston.
99. Sereno D, Maia C & Aït-Oudhia K (2012) Antimony-resistance and environment: elusive links to explore during Leishmania life cycle. Int J Parasitol Drugs Drug Resist 2: 200-2003.
100. Shinondo CJ, Lanners HN, Lowrie RC Jr & Wiser MF (1994) Effect of pyrimethamine resistance on sporogony in a Plasmodium berghei/Anopheles stephensi model. Exp Parasitol 78: 194-202.
101. Sibley CH, Guerin PJ & Ringwald P (2010) Monitoring antimalarial resistance: launching a cooperative effort. Trends Parasitol 26: 221-224.
102. Sinden RE, Dawes EJ, Alavi Y et al. (2007) Progression of Plasmodium berghei through Anopheles stephensi is density-dependent. PLoS Pathog 3: e195.
103. Spence PJ, Jarra W, Levy P, Nahrendorf W & Langhorne J (2012) Mosquito transmission of the rodent malaria parasite Plasmodium chabaudi. Malar J 11: 407.
104. Stauch A, Duerr HP, Dujardin JC, Vanaerschot M, Sundar S & Eichner M (2012) Treatment of visceral leishmaniasis: model-based analyses on the spread of antimony-resistant L. donovani in Bihar, India. PLoS Negl Trop Dis 6: e1973.
105. Steiner K, Garbe A, Diekerman HW & Novak H (1976) The fate of praziquantel in the organism. I: pharmacokinetics in animals. Eur J Drug Metab Pharmacokinet 1: 85-95.
106. Sundar S, More DK, Singh MK, Singh VP, Sharma S, Makharia A, Kumar PC & Murray HW (2000) Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic. Clin Infect Dis 31: 1104-1107.
107. Sundar S, Sinha PK, Rai M et al. (2011) Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial. Lancet 377: 477-486.
108. Sundar S, Singh A, Rai M, Prajapati VK, Singh AK, Ostyn B, Boelaert M, Dujardin JC & Chakravarty J (2012) Efficacy of miltefosine in the treatment of visceral leishmaniasis in India after a decade of use. Clin Infect Dis 55: 543-550.
109. Sutherland CJ, Alloueche A, Curtis J, Drakeley CJ, Ord R, Duraisingh M, Greenwood BM, Pinder M, Warhurst D & Targett GA (2002) Gambian children successfully treated with chloroquine can harbor and transmit Plasmodium falciparum gametocytes carrying resistance genes. Am J Trop Med Hyg 67: 578-585.
110. Temu EA, Kimani I, Tuno N, Kawada H, Minjas JN & Takagi M (2006) Monitoring chloroquine resistance using Plasmodium falciparum parasites isolated from wild mosquitoes in Tanzania. Am J Trop Med Hyg 75: 1182-1187.
111. Thiele EA, Sorensen RE, Gazzinelli A & Minchella DJ (2008) Genetic diversity and population structuring of Schistosoma mansoni in a Brazilian village. Int J Parasitol 38: 389-399.
112. Utzinger J, Xiao SH, Tanner M & Keiser J (2007) Artemisinins for schistosomiasis and beyond. Curr Opin Investig Drugs 8: 105-116.
113. Valentim CL, LoVerde PT, Anderson TJ & Criscione CD (2009) Efficient genotyping of Schistosoma mansoni miracidia following whole genome amplification. Mol Biochem Parasitol 166: 81-84.
114. Van Wyk JA (2001) Refugia-overlooked as perhaps the most potent factor concerning the development of anthelmintic resistance. Onderstepoort J Vet Res 68: 55-67.
115. Vanaerschot M, Decuypere S, Berg M, Roy S & Dujardin JC (2012) Drug-resistant microorganisms with a higher fitness - can medicines boost pathogens? Crit Rev Microbiol. DOI: 10.3109/1030841X.2012.716818 [Epub ahead of print].
116. Walliker D, Quakyi IA, Wellems TE, McCutchan TF, Szarfman A, London WT, Corcoran LM, Burkot TR & Carter R (1987) Genetic analysis of the human malaria parasite Plasmodium falciparum. Science 236: 1661-1666.
117. Walliker D, Hunt P & Babiker H (2005) Fitness of drug-resistant malaria parasites. Acta Trop 94: 251-259.
118. Wang X, Mu J, Li G, Chen P, Guo X, Fu L, Chen L, Su X & Wellems TE (2005) Decreased prevalence of the Plasmodium falciparum chloroquine resistance transporter 76T marker associated with cessation of chloroquine use against P. falciparum malaria in Hainan, People's Republic of China. Am J Trop Med Hyg 72: 410-414.
119. Wang W, Wang L & Liang YS (2012) Susceptibility or resistance of praziquantel in human schistosomiasis: a review. Parasitol Res 111: 1871-1877.
120. Wargo AR, Huijben S, de Roode JC, Shepherd J & Read AF (2007) Competitive release and facilitation of drug-resistant parasites after therapeutic chemotherapy in a rodent malaria model. P Natl Acad Sci USA 104: 19914-19919.
121. Warhurst DC & Duraisingh MT (2001) Rational use of drugs against Plasmodium falciparum. Trans R Soc Trop Med Hyg 95: 345-346.
122. Watkins WM & Mosobo M (1993) Treatment of Plasmodium falciparum malaria with pyrimethamine-sulfadoxine: selective pressure for resistance is a function of long elimination half-life. Trans R Soc Trop Med Hyg 87: 75-78.
123. Webster JP, Gower CM & Norton AJ (2008) Evolutionary concepts in predicting and evaluating the impact of mass chemotherapy schistosomiasis control programmes on parasites and their hosts. Evol Appl 1: 66-83.
124. White NJ (2002) The assessment of antimalarial drug efficacy. Trends Parasitol 18: 458-464.
125. William S, Sabra A, Ramzy F, Mousa M, Demerdash Z, Bennett JL, Day TA & Botros S (2001) Stability and reproductive fitness of Schistosoma mansoni isolates with decreased sensitivity to praziquantel. Int J Parasitol 31: 1093-1100.
126. Witkowski B, Khim N, Chim P et al. (2013) Reduced artemisinin susceptibility of Plasmodium falciparum ring stages in Western Cambodia. Antimicrob Agents Chemother 57: 914-923.
127. Wootton JC, Feng X, Ferdig MT, Cooper RA, Mu J, Baruch DI, Magill AJ & Su XZ (2002) Genetic diversity and chloroquine selective sweeps in Plasmodium falciparum. Nature 418: 320-323.
128. Wyllie S, Cunningham ML & Fairlamb AH (2004) Dual action of antimonial drugs on thiol redox metabolism in the human pathogen Leishmania donovani. J Biol Chem 279: 39925-39932.
129. Xianyi C, Liying W, Jiming C, Xiaonong Z, Jiang Z, Jiagang G, Xiaohua W, Engels D & Minggang C (2005) Schistosomiasis control in China: the impact of a 10-year World Bank Loan Project (1992-2001). Bull World Health Organ 83: 43-48.
130. Xiao SH, Mei JY & Jiao PY (2011) Effect of mefloquine administered orally at single, multiple, or combined with artemether, artesunate, or praziquantel in treatment of mice infected with Schistosoma japonicum. Parasitol Res 108: 399-406.
131. Xu DS, Curtis J, Feng ZL & Minchella DJ (2005) On the role of schistosome mating structure in the maintenance of drug resistant strains. Bull Math Biol 67: 1207-1226.
132. Yardley V, Ortuno N, Llanos-Cuentas A et al. (2006) American tegumentary leishmaniasis: is antimonial treatment outcome related to parasite drug susceptibility? J Infect Dis 194: 1168-1175.